# Safety and Efficacy Study in Infant With SBS

> **NCT02865122** · PHASE2,PHASE3 · TERMINATED · sponsor: **Elgan Pharma Ltd.** · enrollment: 2 (actual)

## Conditions studied

- Short Bowel Syndrome

## Interventions

- **DRUG:** NTRA-9620
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02865122
- **Lead sponsor:** Elgan Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-20
- **Primary completion:** 2018-03-22
- **Final completion:** 2018-03-22
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Sponsor decision based on enrollment
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02865122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02865122, "Safety and Efficacy Study in Infant With SBS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02865122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*